PBI-1402 is a small molecule synthetic compound with oral Bioavailability. The compound activates neutrophils, enhancing their survival and activation with comparable efficacy to GM-CSF, G-CSF and EPO, which are currently... However, it has been shown that when co-administered with these compounds, effects are additive, making PBI-1402 an excellent candidate for combination therapy and asserting its independent mechanism of action.
- Mechanism
- Curator reviewed
PBI-1402 activates neutrophils, enhancing their survival and activation with comparable efficacy to GM-CSF, G-CSF and EPO, which are currently used to treat anemia. However, it has been shown that when co-administered with these compounds, effects are additive, making PBI-1402 an excellent candidate for combination therapy and asserting its independent mechanism of action. PBI-1402 appears to work on the PMN pathway, but its specific binding properties are not known.
- Primary indication
- Investigated for use/treatment in adverse effects (chemotherapy), anemia, and chemotherapy.Curator reviewed
- Code names
- PBI-1402
Which companies are running trials of PBI-1402, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account